HIV (human immunodeficiency virus) is a virus that attacks the body’s immune system, weakening the response to infections or cancers and increasing the risk of cardiovascular problems and other complications. Currently there is no effective cure, although the administration of new antiretrovirals can contain the infection until it becomes asymptomatic, requiring lifelong treatment.
According to the latest data from the WHO, this disease continues to be one of the biggest problems for global public health, with 36.3 million lives lost and some 37.7 million infected by the end of 2020.
On February 15, UCLA researchers presented at a conference in Denver (Colorado), the case of the first HIV-infected woman who could have been cured after stem cell transplantation from the umbilical cord.
This American woman, who remains anonymous, was treated for 4 years with specialized stem cell transplants as a treatment for acute myeloid leukemia. According to Dr. Yvonne Bryson, who is leading the clinical study, since the patient stopped antiretroviral therapy 14 months ago, she has not seen any rebound in infection.
To date, only two men had been cured after allogeneic transplantation of homozygous adult stem cells CCR5-delta 32/32, a mutation that protects against HIV-1, some from bone marrow and others from blood cells. Therefore, this American woman could become the first cured with stem cells from the umbilical cord.
As Bryson explains “This study provides hope for the use of cord blood cells or a combination of cord blood cells and haploidentical (half-matched) grafts to achieve HIV-1 remission for individuals requiring transplantation for other diseases. It also provides proof that HIV-1 viral ‘reservoirs’ can be cleared sufficiently to afford remission and possibly cure in the setting of resistant target cells,”
The use of umbilical cord blood banks could be a potential resource for the cure of numerous diseases. ““Adult donor grafts provide many cells initially and rapid engraftment, but histocompatibility can be an issue leading to risk of graft-versus-host disease. Umbilical cord blood grafts have a lower cell dose and take longer to engraft, but they can be banked for ready availability, and they pose less risk for GVHD,” Bryson said. With the combination of adult and umbilical cord grafts, a rapid response is obtained first, for which the adult cells are responsible, and later, greater efficacy over time thanks to the action of the cord cells, which decrease the necessary level of compatibility between donor and recipient to avoid rejection, thus expanding the number of potential recipients.